Boehringer Ingelheim: Diabetes Mellitus, Type 2 trials
The registry lists 130 Diabetes Mellitus, Type 2 studies with Boehringer Ingelheim as lead sponsor. 2 are open to participants now and 109 have results posted.
Phase 1 19Phase 2 18Phase 3 50Phase 4 9No phase 34(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DMCompletedNCT00736099Phase 3Results posted
- The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic PatientsCompletedNCT00716092Phase 2Results posted
- Japanese P III vs Voglibose and PlaceboCompletedNCT00654381Phase 3Results posted
- Efficacy vs Placebo as Initial Combination Therapy With PioglitazoneCompletedNCT00641043Phase 3Results posted
- Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00622284Phase 3Results posted
- Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic ControlCompletedNCT00621140Phase 3Results posted
- BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 DiabetesCompletedNCT00602472Phase 3Results posted
- Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 DiabetesCompletedNCT00601250Phase 3Results posted
- 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 DiabetesCompletedNCT00558571Phase 1Results posted
- Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes PatientsCompletedNCT00328172Phase 2Results posted
- Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 DiabetesCompletedNCT00309608Phase 2Results posted
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightCompletedNCT06066528Phase 3
- Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in FranceActive, not recruitingNCT05882071
- Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line SulfonylureasWithdrawnNCT05102071
- Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. AcarboseTerminatedNCT04180813
- Comparative Effectiveness of Empagliflozin in the USCompletedNCT03363464
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 DiabetesTerminatedNCT02212925Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 DiabetesCompletedNCT02211963Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesCompletedNCT02183415Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 DiabetesCompletedNCT02183350Phase 1
- BI 1356 BS in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02183324Phase 2
- Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without MetforminCompletedNCT02150824Phase 2
- Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 DiabetesWithdrawnNCT01984606Phase 3
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes MellitusCompletedNCT01874483Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 DiabetesCompletedNCT01282970Phase 1
- Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy VolunteersCompletedNCT01146886Phase 1
- 4 Weeks Treatment of Type II Diabetic Patients With BI 44847CompletedNCT00558909Phase 1
- DETAIL Study: Diabetes Exposed to Telmisartan and EnalaprilCompletedNCT00274118Phase 3
- Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 DiabetesCompletedNCT00240422Phase 4
- SMOOTH - Blood Pressure Control in Diabetic/Obese PatientsCompletedNCT00239538Phase 4